AT-527 + digoxin

AT-527 + digoxin is a combination of two pharmaceutical agents used in clinical research to assess potential drug-drug interactions. - **AT-527** is an investigational oral antiviral prodrug (a guanosine nucleotide analog) developed for the treatment of viral infections, notably hepatitis C and COVID-19. It acts by inhibiting the viral RNA-dependent RNA polymerase, thereby blocking viral replication. - **Digoxin** is a cardiac glycoside used primarily for heart failure and atrial fibrillation; it increases myocardial contractility (positive inotropy) and decreases heart rate (negative chronotropy) by inhibiting the sodium-potassium ATPase pump, leading to increased intracellular calcium in cardiac cells. The combination has been studied specifically to evaluate pharmacokinetic interactions between AT-527 and digoxin, as both drugs may be substrates or inhibitors of drug transporters such as P-glycoprotein[1].